Trump’s Tariff Bomb: Global Pharma Rattled, Indian Generics in the Crosshairs
In a move that stunned the pharmaceutical world, US President Donald Trump unveiled a 100% tariff on all imported branded and patented drugs, effective October 1, 2025. This sweeping policy, announced via social media, signals a dramatic escalation in America’s protectionist agenda. While generic medicines—the lifeblood of India’s $20-billion export trade to the US—are technically exempt, the industry’s nerves are frayed as experts warn the scope could widen at any moment.
“Starting 1 October 2025, we will impose a 100 per cent tariff on any branded or patented pharmaceutical product unless a company is building their pharmaceutical manufacturing plant in America,” Trump declared. Only firms with US manufacturing projects underway will be spared. For Indian pharma giants, whose fortunes are tightly bound to the US market, the shock was immediate and palpable.
Market Shock: Indian Pharma Stocks Plunge, Uncertainty Looms
On the day following Trump’s announcement, Indian pharmaceutical stocks tumbled sharply. Sun Pharma, India’s largest drugmaker, dropped as much as 5% before stabilizing at a 2.6% loss. Others, like Biocon, Aurobindo Pharma, Cipla, Dr Reddy’s, Zydus Life, Lupin, and Gland Pharma, all felt the sting, reflecting widespread investor anxiety. These companies collectively account for about 70% of India’s drug exports to the US, making them highly sensitive to American policy shifts.
But as the dust settled, a more nuanced picture emerged. Analysts, including Tushar Manudhane of Motilal Oswal, pointed out that the new tariffs target branded and patented drugs, not generics. “Given the duties announced are on branded/patented drugs, there would be no impact on the generics exports done by Indian pharma companies. The major portion of exports to the US is generic medicine. So we believe it is business as usual for generic pharma companies,” Manudhane noted. The immediate impact, then, is expected to be minimal for most Indian exporters.
The Hidden Risks: Complex Generics and Biosimilars in the Grey Zone
Despite the initial sigh of relief, industry observers are wary. The tariff’s language leaves room for ambiguity—especially concerning complex generics and specialty medicines. These are drugs with intricate formulations or delivery mechanisms, often used for rare or chronic conditions. Biosimilars, which are close copies of cutting-edge biologics, also fall into this grey area.
Should the US extend tariffs to these advanced segments, the financial hit could be substantial. For example, Sun Pharma’s flagship psoriasis drug, Ilumya, produced outside the US, faces direct exposure. If tariffs double its cost, patients may end up shouldering higher prices, or companies may be forced to absorb the blow. “Uncertainty still remains over whether complex generics and biosimilars will come under the tariff embargo in the future,” cautioned Pankaj Pandey of ICICI Securities.
The US is India’s biggest pharmaceutical market, accounting for about 35% of exports, or roughly $10 billion in 2025 alone (Telegraph India). Margins for generics are already razor-thin, and any expansion of tariffs could threaten the delicate balance many companies rely on.
Trade Tensions and Global Ramifications
Trump’s announcement comes against a backdrop of rising US-India trade tensions and a stalled bilateral trade deal. In fact, India’s pharma exports to the US dropped from $745 million in May to $647 million in August 2025 (Livemint), a dip analysts attribute to the tariff threat and broader trade uncertainty. Rahul Ahluwalia of the Foundation for Economic Development warned, “We should redouble efforts to get a trade deal with the US and EU to enable our industries to have access to large markets.”
Globally, pharmaceutical heavyweights such as AstraZeneca, Roche, Merck, Biogen, and Pfizer are scrambling to expand US-based manufacturing to dodge the new tariffs. Indian firms with existing US plants may be shielded, but building new facilities is no quick fix—experts estimate it could take five to ten years, with regulatory hurdles and labor shortages compounding the challenge.
Pharmexcil Chairman Namit Joshi offered some reassurance: “The proposed tariff on branded drugs is unlikely to have an immediate impact on Indian exports, as the bulk of our contribution lies in simple generics and most large Indian companies already operate US manufacturing or repackaging units and are exploring further acquisitions.”
The US Consumer: Caught in the Crossfire
While India’s generics industry may escape the worst for now, American consumers could find themselves paying the price. Experts interviewed by NewsGram and IANS argue that Trump’s tariffs will drive up costs for US patients, potentially making life-saving medicines unaffordable for many. “This will not harm India, but only the US. The tariff imposed by America is very wrong,” said businessman Dr. Niranjan Hiranandani.
Akash Jindal, an economist, echoed the sentiment: “By placing the tariff, the US is escalating the price of medicines, which its citizens will consume. Does the US think that by October 1, they would be able to set up a new factory in the country?” He warned that a backlash from American consumers is likely, especially as drug prices in the US are already among the highest in the world.
From oncology treatments to chronic disease therapies, India supplies over 45% of generic and 15% of biosimilar drugs used in the US (NewsGram). For now, these affordable medicines are the backbone of the US healthcare system—any disruption could have far-reaching consequences.
Industry Response: Bracing for What Comes Next
As Monday approaches, market watchers expect a sharp rebound for Indian pharma stocks, buoyed by the realization that generics remain outside Trump’s tariff crosshairs—for now. Yet, the mood remains cautious. Investors and executives alike are scanning for signs that the president’s protectionist zeal might sweep up more categories of drugs, or spark a wider trade war.
For Indian pharma, the message is clear: diversify, invest in US-based operations, and prepare for a more volatile global landscape. The government, too, faces a challenge—securing trade deals to keep vital markets open and protect an industry that not only supports millions of jobs but also helps stabilize global healthcare systems.
Trump’s tariff shock may have spared India’s generics for the moment, but the uncertainty that now hangs over global pharmaceutical supply chains is a reminder of how swiftly political agendas can reshape entire industries. The next chapter will be written not just in boardrooms and trading floors, but in the lives of patients around the world who depend on affordable, reliable medicines.